Siphoviridae LL5.
A bacteriophage strain targeting harmful gut bacteria. Part of the PreforPro phage blend. Hunts and destroys specific harmful bacteria in your gut, shifting the balance toward a healthier microbiome.
Reviewed March 2026
- Category
- General
- Also filed under
- Targets specific harmful gut bacteriaSupports microbiome diversityPart of studied PreforPro blend
What Siphoviridae LL5 is, and what it does.
- Does it work
- The phage concept is brilliant and the science is real. But LL5 has never been studied alone. All evidence comes from the 4-phage PreforPro blend. You're buying the team, not the player.
- How much to take
- 15 mg as part of the full PreforPro blend. No standalone dosing exists because it's never been tested in isolation.
- Time to feel it
- Phage activity shows up in stool bacterial counts rather than in sensation. The blend studies measured shifts across about 4 weeks, so a month of daily use is the honest window.
- The first dose
- Zero noticeable effects. The phages are working at a microscopic level immediately, but you won't feel a thing.
- With regular use
- Weeks 3-4: some users report subtle improvements in digestive comfort. The blend studies showed statistically modest but real changes in gut bacteria composition.
- How well tolerated
- About as safe as supplements get. Phages can't infect human cells. Period. They're part of your normal gut ecology already.
- How it feels
- Invisible. The work happens at a bacterial level you can't sense. Any benefits manifest as gradual digestive improvements, not a noticeable sensation.
- The overlooked benefit
- Phage numbers track how much of their target bacterium is present rather than how much you took, so the preparation behaves like a self-limiting population, not a fixed exposure.
15mg a day is where Siphoviridae LL5 works.
Source: Gindin et al., 2019 (PreforPro blend study)
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Selectively kills harmful gut bacteria
- Supports probiotic colonization
Questions people ask about Siphoviridae LL5.
- What makes Siphoviridae different from the other phages in PreforPro?
- Each phage family targets different bacteria. Siphoviridae have long flexible tails and tend to target different bacterial species than Myoviridae phages. Together, they cover more ground.
- Can bacteria become resistant to phages?
- Yes, but phages evolve too. It's an arms race that's been going on for billions of years. Multi-phage cocktails (like PreforPro) make resistance much harder for bacteria to develop.
- Are phages better than probiotics?
- Different tools, different jobs. Phages remove bad bacteria. Probiotics add good bacteria. They actually work better together than either alone.
- How do I know the phages are alive in my supplement?
- Look for products that list phage viability or plaque-forming units (PFU). PreforPro is tested for viability. Dead phages don't work.
- Will this mess up my microbiome?
- The opposite. Phages are incredibly targeted. They only kill their specific bacterial host. Everything else in your microbiome is completely untouched.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
This lytic phage targets defined Escherichia coli strains and leaves lactic acid bacteria untouched, so lysing the target population frees nutrients and attachment sites. Co dosed probiotic strains are the ones able to take up that space.
Narrow phage host range means the delivered Lactobacillus carries none of the receptors the phage needs and passes through intact. Competition in the shared niche narrows while the strain is preserved.
Coliform phages cannot adsorb to Lactobacillus rhamnosus, so the two are stable in one formula. The phage acts only on the competing coliform population in the same environment.
A lytic bacteriophage can only replicate where its host species is present and metabolically active, so anything that changes host density changes phage dynamics. Inulin selectively feeds bifidobacteria and some lactobacilli, which is a different part of the community than most phage targets. The direction of any net effect depends on which species the phage recognises. It supports normal microbial balance in the colon. No combination has been measured for this particular phage.
Phage preparations are usually positioned as clearing space that beneficial organisms then occupy, and a fermentable substrate is what lets those organisms take the space. The two act at different points of the same sequence rather than on the same target. Whether that sequence plays out as described has not been measured for this phage. The pairing is formulation logic supported by general microbial ecology.
Phage host ranges are narrow by nature, usually confined to particular strains within a species, which is the basis of the selectivity claim made for phage preparations generally. Feeding a non-target group at the same time is a coherent pairing. Nothing here has been demonstrated for Siphoviridae LL5 specifically. The combination supports normal colonic microbial composition.
Phage preparations are commonly formulated alongside probiotic strains on the reasoning that reducing competing organisms eases colonisation. Bifidobacteria are not typical Siphoviridae hosts in the products these preparations appear in, so co-administration is plausible on paper. The colonisation effect itself has not been shown for this phage with this strain. Read it as the formulation's own rationale rather than a measured result.
Formulas that carry a phage cocktail typically pair it with several lactobacilli, on the reasoning that the phage narrows competition while the strains fill the space. Any lactobacillus is itself a potential phage host depending on the phage's receptor specificity, which is worth knowing rather than assuming away. Host range data for this particular phage against this strain are what would settle it. Until then the pairing is a formulation convention.
Bacteriophages attach to bacterial surface structures such as teichoic acids, lipopolysaccharide or pili, none of which exist on a fungal cell wall. Saccharomyces boulardii is therefore structurally immune to phage predation, which makes it a straightforward companion in any phage-containing formula. This is settled virology rather than a tested pairing. It supports normal gut microbial balance through an entirely separate route.
Where a phage narrows a competing population, the expected consequence is more substrate reaching butyrate producers. Supplying butyrate directly delivers the endpoint without depending on that chain of events happening. The two approach the same outcome from opposite ends. Neither has been measured alongside the other for this phage.
Phage capsid stability falls sharply below about pH 3, and survival through the stomach is the central formulation problem for any oral phage product. Deliberately acidifying the stomach with betaine hydrochloride works against that. This is established phage physical chemistry, not a claim about a particular product. Enteric coating or buffering exists precisely to address it.
Buffering agents are used in phage delivery research for exactly this reason: acid inactivation is the main loss route between swallowing and the colon. Sodium bicarbonate raises gastric pH transiently, which would be expected to preserve more infective particles. The principle is established. The magnitude for any particular preparation and dose has not been quantified here. Enteric encapsulation achieves the same goal by a different route.
Charcoal's surface binds a broad range of organic material in the gut lumen, and a protein-coated virion is a plausible binding target. Taking the two together would be expected to reduce the number of infective particles reaching their hosts. The adsorption principle is well established even though this specific pair has not been measured. Separating the two by several hours is the usual handling of any charcoal interaction.
Montmorillonite clays bind virus particles through electrostatic and surface interactions well enough to be used for virus removal in water processing. That same property would apply to an ingested phage preparation sharing the lumen with clay. The mechanism is established colloid chemistry rather than a gut study. Spacing the two apart in the day is the practical implication.
Lactoferrin's antibacterial action includes direct binding to lipopolysaccharide on gram-negative surfaces, and lipopolysaccharide is a common phage receptor. Occupying the same surface structures could interfere with adsorption, or could sensitise the cell by disrupting the envelope. Which of those dominates has not been established for this pair. It is a mechanistic flag rather than a directional recommendation.
Different fibres select for different genera, and the resident community determines both which hosts are available and how quickly a phage population rises or falls. Resistant starch favours a distinct set of colonic organisms from inulin-type fructans. The interaction is community ecology, well described in general and unmeasured for this phage. It supports normal fermentation patterns in the colon.
Talk to a doctor before taking Siphoviridae LL5 if any of these apply to you: Individual strain not studied in isolation, Bacteriophage therapy is still emerging. These are flags to check first, not effects Siphoviridae LL5 is known to cause.
Not medical advice. Show the label to your pharmacist.What Siphoviridae LL5 actually does.
Siphoviridae are tailed bacteriophages with a long, non-contractile tail and a double-stranded DNA genome. The shape was defined under the electron microscope and has since been folded into a wider taxonomy.
A bacteriophage finds its host through specific surface receptors such as teichoic acids, lipopolysaccharide or pili, so host ranges are usually confined to particular strains within a single species.
In the lytic cycle the phage injects its genome, hijacks the host's synthesis machinery to build new particles, then phage-encoded endolysin and holin proteins split the cell open and the new phages spill out.
A phage can't infect eukaryotic cells at all. There's nothing for it to bind on the human intestinal lining, and it only copies itself where its bacterial host is present.
Where Siphoviridae LL5 comes from.
It is grown, not made. The bacteria it attacks are cultured first, the phage is added and multiplies until the culture clears, then everything bacterial is filtered out and what remains is counted by seeing how many spots it makes on a fresh bacterial lawn. That count, in plaque forming units, is what goes on the label.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
Production begins with a culture of the specific bacterial host the phage infects, grown in a defined broth to the density where infection is most productive.
The phage stock is added at a set multiplicity of infection and the culture is held until lysis clears it, at which point the broth contains progeny particles along with host cell debris.
The lysate is centrifuged and passed through membrane filters, typically 0.22 micron, which retains bacterial cells and debris while phage particles pass through. Further polishing steps target endotoxin from the gram-negative host.
Content is assigned by plaque forming units on a lawn of the host organism, which counts infective particles rather than total protein or DNA.
The titred preparation is lyophilised with a cryoprotectant for dry blending, or held as a buffered suspension where cold chain allows.
Getting Siphoviridae LL5 from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In adults, a supplemental bacteriophage preparation taken alongside Bifidobacterium animalis subsp. lactis BL04 was compared with the probiotic alone for effects on gut bacteria and digestive comfort.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
These are the studies our verdict leans on, chosen from the 9 we read for Siphoviridae LL5. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
